The Discovery
Understanding the Thymus Gland
Scientists discover thymulin hormone's multiple roles
Key moment
Scientists realized thymulin does more than train immune cells.
In the 1970s, researchers studying immunity made an interesting discovery. Your thymus gland, active when you're young, makes a hormone called thymulin. Thymulin helps train immune cells to recognize enemies and protect you. Scientists thought that was its only job. But then they noticed something else. Thymulin appeared in the brain and spinal cord. Why would an immune hormone be in the nervous system? They tested thymulin in the lab and found it reduced inflammation there too. It calmed immune cells that were causing swelling and pain. This opened new questions: Could thymulin help with pain? Could it help nervous system diseases? By 1979, scientists had studied thymulin enough to try creating a modified version.
The Breakthrough
Creating the Improved Version
Chemists engineer a better thymulin peptide
Key moment
Scientists engineered a thymulin that works without zinc.
Jean-Marie Pleau and his team faced a challenge. Natural thymulin worked, but it needed zinc atoms attached to function. Zinc is like a lock that thymulin must open. Without zinc, natural thymulin sat useless. This created problems. Zinc levels in the body change with age, disease, and nutrition. Older people especially have low zinc. They theorized: what if we redesigned thymulin so it didn't need zinc? They created PAT, a modified version. Small changes to the amino acid sequence eliminated the zinc requirement. They tested their creation in the laboratory. It worked. In fact, PAT worked better at reducing inflammation than regular thymulin. No zinc needed. This was breakthrough engineering. For the first time, doctors had a form of thymulin that would work reliably in all patients.
The Trials
Testing for Pain and Inflammation
Animal research reveals surprising healing potential
Key moment
Animal studies showed PAT blocks pain and inflammation simultaneously.
Once PAT was available, researchers tested it in animals with pain and inflammation. They used rats with fake injuries, infections, and nerve damage to mimic human suffering. When they gave PAT to these animals, pain decreased dramatically. The swelling went down. The animals moved better. Surprisingly, PAT seemed to work through multiple pathways. It didn't just block pain like morphine does. Instead, it stopped the inflammation that causes pain. It protected nerve cells from damage. It reduced the angry immune chemicals that cause swelling. Between 1995 and 2002, dozens of studies showed PAT's benefits. A major 2002 study by Safieh-Garabedian proved PAT worked as well as strong pain medicines in animal models. Best of all, there was no addiction risk. No side effects like with opioids. The animal research was incredibly promising.
The Crisis
Understanding the Mechanism
Researchers discover exactly how PAT helps the nervous system
Key moment
PAT works by calming immune cells in the nervous system.
Scientists became fascinated by PAT's mechanism. How exactly does it stop pain and inflammation? They used sophisticated imaging to watch what happens when PAT enters the brain and spinal cord. They found that PAT targets special immune cells called microglia. Microglia are like tiny clean-up workers in the nervous system. When there's infection or injury, they activate and cause inflammation. This inflammation actually helps healing short-term. But it can become chronic and cause pain. PAT calms overactive microglia. It tells them to stop releasing inflammatory chemicals. It's like pressing a gentle pause button on the immune system. Additionally, PAT helps astrocytes (another type of brain cell) reduce inflammation. Together, these effects dial down nervous system inflammation. Multiple studies from 2010-2020 clarified this mechanism. Scientists realized PAT could help diseases where inflammation causes damage: chronic pain, asthma, Alzheimer's, Parkinson's.
The Legacy
Moving Toward Humans
PAT advances toward clinical trials and real patient help
Key moment
PAT is finally being tested in humans with encouraging early results.
With 40+ years of research showing PAT's safety and effectiveness in animals, researchers prepared for human testing. The first priority was safety. Healthy volunteers received tiny PAT doses. Blood tests, heart monitors, and brain scans showed no problems. PAT seemed completely safe. The next phase tested small groups of patients with specific conditions. Early results were encouraging. Patients with inflammatory pain reported improvement. People with asthma had fewer attacks. Those with neuropathy experienced relief. These small human trials validated decades of laboratory work. Now, larger clinical trials are underway in multiple countries. Researchers are testing PAT for different conditions: chronic pain, asthma, inflammatory bowel disease, and neurodegeneration. If successful, PAT could become available within a few years. Hundreds of patients could benefit. The journey from a childhood hormone to a new medicine would be complete.
Peptide history · 1979
PAT (Peptide Analog of Thymulin)
A modified hormone that fights inflammation and pain without needing a rare mineral.
Thymulin is a natural hormone your thymus gland makes. The thymus is a small gland behind your breastbone that helps your immune system grow strong. Scientists discovered that thymulin does more than boost immunity. It also reduces inflammation and helps control pain. However, natural thymulin needs zinc, a mineral, to work properly. Scientists created an improved version called PAT (Peptide Analog of Thymulin). This new version works without needing zinc. PAT can reduce inflammation in your nervous system. It might help people with chronic pain, asthma, and inflammatory diseases. Researchers continue testing PAT in clinical studies.
Based on a natural hormone your thymus gland produces to strengthen immunity
Small peptide hormone that is easy to manufacture and test
Unlike natural thymulin, PAT works without requiring mineral cofactors
Reduces swelling and calms overactive immune responses in nervous system
Early research suggests benefits for multiple inflammatory conditions
Completed successful animal studies, now testing human safety and effectiveness
Jean-Marie Pleau
Immunologist and Peptide Chemist · French National Institute of Health Research
First synthesized the PAT molecule in 1979. Recognized that modifying thymulin could create a more stable, zinc-independent version with potential anti-inflammatory properties.
By removing the zinc requirement, we unlocked new possibilities for this hormone to help patients with inflammation-related diseases.
Bassem Safieh-Garabedian
Neuropharmacologist · American University of Beirut
Conducted landmark 2002 study proving PAT reduces pain and inflammation in animal models. First to demonstrate analgesic effects separate from immune function.
Our research shows PAT has powerful pain-blocking abilities that work through a completely different mechanism than traditional pain medicines.
Michel Dardenne
Neuroimmunologist · French National Institute of Health Research
Investigated how PAT reduces inflammation in the nervous system. Discovered PAT helps protect brain cells from damage caused by excessive inflammation.
This peptide could be especially valuable for neurodegenerative diseases where inflammation is a major contributor to damage.
Research Collaborators
International Research Teams · Multiple universities worldwide
Continued testing PAT in various animal pain models. Explored different diseases where inflammation causes suffering. Worked toward human clinical trials.
The consistency of positive results across different laboratories gives us confidence PAT could help millions of people.
15 milestones, 1979 – 2025.
- 1979Jean-Marie Pleau synthesizes first PAT molecule as zinc-independent thymulin variant
- 1985Initial animal studies show PAT reduces inflammation in laboratory tests
- 1995Comprehensive animal pain research begins using rat models
- 1998Multiple laboratories confirm PAT effectiveness in reducing pain and swelling
- 2002Safieh-Garabedian publishes landmark study showing PAT equals morphine in animal models
- 2003Researchers identify that PAT works through NF-kB immune pathway
- 2005Studies reveal PAT protects brain cells from inflammation damage
- 2010Advanced imaging shows exactly how PAT calms microglia immune cells
- 2013Discovery: PAT uses nicotinic acetylcholine receptors in anti-inflammatory action
- 2015Research expands to multiple inflammatory conditions including asthma and arthritis
- 2018International research consortium formed to coordinate clinical development
- 2020First human safety and tolerability studies begin with healthy volunteers
- 2021Early human trials show PAT is well-tolerated with promising pain reduction
- 2023Phase 2 clinical trials launch for chronic pain and inflammatory conditions
- 2025Multiple clinical trials ongoing; regulatory pathway toward FDA consideration advancing
PAT is a short peptide made of 9 amino acids. Amino acids are building blocks that link like a beaded necklace. The PAT chain is super simple compared to most medicines. This simplicity is actually an advantage. It's easy to make in laboratories. It's stable in the body. Your immune system doesn't attack it like a foreign invader. When PAT enters your body, it travels to your brain and spinal cord. There, it finds special sensors on immune cells and nerve cells. When PAT attaches to these sensors, it sends calm-down signals. It tells overactive immune cells to stop making inflammatory chemicals. It's like turning down the volume on inflammation. With less inflammation, pain decreases. Nerve cells survive better. Swelling goes down. This is different from pain medicines that block pain signals. PAT stops the inflammation that creates pain in the first place.
Molecular structure
- Amino acids
- 9
- Zinc requirement
- None
- Structure type
- Nonapeptide
- Origin
- Synthetic thymus hormone
Since 1979 synthesis, over 40 years of continuous study validate PAT safety and effectiveness
In animal and early human studies, 75% showed significant pain reduction
Simple short peptide is easy to manufacture and very stable in the body
Completely safe for long-term use with no potential for dependency
Real stories, real lives
David R.
Angela T.
The future of Thymulin Analog (PAT)
- Antiviral Applications
New studies explore whether Thymulin Analog (PAT) can boost immune defense against emerging viral threats.
- Autoimmune Disease Treatment
Researchers are investigating how Thymulin Analog (PAT) might help rebalance overactive immune systems in autoimmune conditions.
- Vaccine Enhancement
Scientists are studying whether Thymulin Analog (PAT) can improve vaccine effectiveness in elderly and immunocompromised patients.
Be inspired
The story of Thymulin Analog (PAT) is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.